- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01749189
Effect of Protein Blend Supplementation During Exercise Training on Muscle Growth and Strength
October 3, 2019 updated by: DuPont Nutrition and Health
A Randomized, Controlled Double Blind Longitudinal Study: Effect of Protein Blend Supplementation During Exercise Training on Muscle Growth and Strength
This study will investigate the effects of a soy/dairy protein blend on muscle growth and strength.
In sports nutrition and in aging it is important to have healthy muscles.
This can be achieved with exercise and nutrition.
Consumption of protein following resistance exercise can promote healthy muscle growth and help improve strength.
Young healthy men will be studied during a 12 week resistance exercise training program and be given protein supplements every day during the study.
The hypothesis is that a blend of soy, whey and casein will induce a greater muscle gain and strength increase than the control.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
58
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Galveston, Texas, United States, 77555
- University of Texas Medical Branch
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 35 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Stable body weight, healthy, males aged 18-35
Exclusion Criteria:
- Exercise training (>2 weekly sessions of moderate to high intensity aerobic or resistance exercise)
- Resistance Training (>2 weekly sessions of moderate to high intensity) within the past six months
- Any orthopedic injury that prohibits participation in the exercise training
- Significant heart, liver, kidney, blood, or respiratory disease
- Peripheral vascular disease
- Diabetes mellitus or other untreated endocrine disease
- Active cancer (all groups) and history of cancer
- Acute infectious disease or history of chronic infections (e.g. TB, hepatitis, HIV, herpes)
- Recent (within 6 months) treatment with anabolic steroids, or corticosteroids.
- Alcohol or drug abuse
- Tobacco use (smoking or chewing)
- BMI range will be (20-29.9 kg/m2) to exclude for Malnutrition (hypoalbuminemia, and/or hypotransferrinemia) and Obesity
- Low hemoglobin levels (below normal values)
- Food allergies (including milk and soy)
- Individuals on a Vegetarian Diet
- Females
- Average protein intake < 0.6 or >1.8 g/kg per day
- Taking dietary supplements such as green tea, creatine, ribose, whey or soy protein, etc. within the past 6 months
- Currently on a high-soy diet or high dairy diet (consuming >2 servings of soy per day or >6 servings of dairy)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
Placebo dry blended beverage (carbohydrate)
|
22 grams of carbohydrate/day
|
|
Experimental: Blend
A dry blended beverage containing a protein blend of soy, whey and casein
|
22 grams of protein/day
|
|
Active Comparator: Whey
A dry blended beverage containing Whey protein
|
22 grams of protein/day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Muscle Mass
Time Frame: Baseline, 6 weeks, 12 weeks
|
Muscle Mass will be determined by DEXA
|
Baseline, 6 weeks, 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Muscle Strength
Time Frame: Baseline, 6 weeks, 12 weeks
|
Knee Extensor
|
Baseline, 6 weeks, 12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Mark B Cope, PhD, Solae, LLC
- Principal Investigator: Blake Rasmussen, PhD, University of Texas
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Reidy PT, Fry CS, Igbinigie S, Deer RR, Jennings K, Cope MB, Mukherjea R, Volpi E, Rasmussen BB. Protein Supplementation Does Not Affect Myogenic Adaptations to Resistance Training. Med Sci Sports Exerc. 2017 Jun;49(6):1197-1208. doi: 10.1249/MSS.0000000000001224.
- Reidy PT, Borack MS, Markofski MM, Dickinson JM, Deer RR, Husaini SH, Walker DK, Igbinigie S, Robertson SM, Cope MB, Mukherjea R, Hall-Porter JM, Jennings K, Volpi E, Rasmussen BB. Protein Supplementation Has Minimal Effects on Muscle Adaptations during Resistance Exercise Training in Young Men: A Double-Blind Randomized Clinical Trial. J Nutr. 2016 Sep;146(9):1660-9. doi: 10.3945/jn.116.231803. Epub 2016 Jul 27.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2012
Primary Completion (Actual)
May 1, 2014
Study Completion (Actual)
June 1, 2014
Study Registration Dates
First Submitted
November 15, 2012
First Submitted That Met QC Criteria
December 12, 2012
First Posted (Estimate)
December 13, 2012
Study Record Updates
Last Update Posted (Actual)
October 7, 2019
Last Update Submitted That Met QC Criteria
October 3, 2019
Last Verified
October 1, 2019
More Information
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Muscle
-
United States Army Research Institute of Environmental...US Army Natick Soldier Research, Development & Engineering CenterCompletedMuscle Loss | Muscle Anabolism | Muscle PerformanceUnited States
-
PepsiCo Global R&DRecruitingMuscle Damage | MuscleUnited States
-
United States Army Research Institute of Environmental...Tufts UniversityCompletedMuscle Loss | Muscle AnabolismUnited States
-
Çağtay MadenCompletedForward Head Posture | Muscle Tone | Muscle Stiffnes | Muscle Elasticty | Vital CapacityTurkey
-
University Hospital, Basel, SwitzerlandMedical University Innsbruck; University Hospital, Zürich; Cantonal Hospital... and other collaboratorsActive, not recruitingMuscle Weakness | Muscle Atrophy | Muscle Spasticity | Muscle Cramp | Muscle Soreness | Muscle Damage | Myopathy | Muscle InjurySwitzerland, Austria
-
Koç UniversityCompletedMuscle Strength | Posture | Abdominal MuscleTurkey
-
King Saud UniversityCompletedRehabilitation | Muscle Strength | Quadriceps MuscleSaudi Arabia
-
University of Texas Southwestern Medical CenterAbhimanyu Garg; Prishant Mishra; Jimin RenCompletedMuscle Weakness | Muscle Cramp | Muscle Stiffness | Statin-related Muscle Pain | Muscle AchesUnited States
-
University Hospital, Strasbourg, FranceTerminated
-
Neuromed IRCCSRecruitingSpasticity, Muscle | Muscle Tone Abnormalities | Rigidity, MuscleItaly
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
AkesoNot yet recruitingAtopic DermatitisChina
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States